
BCEL
Healthcare · Biotechnology · $3.6M market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2023
EPS trend, 90 days to now · 0.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 14, 2023 | After the close | -0.38 | -0.39 | -2.6% |
| Aug 10, 2023 | After the close | -0.57 | -0.49 | +14.0% |
| May 10, 2023 | After the close | -0.56 | -0.54 | +3.6% |
| Mar 29, 2023 | After the close | -0.59 | -0.53 | +10.2% |
| Nov 10, 2022 | After the close | -0.73 | -0.60 | +17.8% |
| Aug 8, 2022 | After the close | -0.71 | -0.72 | -1.4% |
| May 11, 2022 | Before the open | -0.78 | -0.65 | +16.7% |
| Mar 3, 2022 | After the close | -0.75 | -0.79 | -5.3% |
| Nov 2, 2021 | Before the open | -0.74 | -0.74 | 0.0% |
| Aug 11, 2021 | After the close | -0.69 | -0.72 | -4.3% |
| May 12, 2021 | After the close | -0.65 | -0.70 | -7.7% |
| Feb 25, 2021 | After the close | -0.64 | -0.63 | +1.6% |
| Nov 12, 2020 | Before the open | -0.61 | -0.66 |
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian,…
| -8.2% |
| Aug 12, 2020 | Before the open | -0.76 | -0.71 | +6.6% |
| May 14, 2020 | After the close | -0.73 | -0.73 | 0.0% |
| Mar 11, 2020 | After the close | -0.64 | -0.72 | -12.5% |
| Nov 12, 2019 | After the close | -0.73 | -0.57 | +21.9% |
| Aug 13, 2019 | After the close | -0.79 | -3.67 | -364.6% |
| Jun 20, 2019 | After the close | 0.00 | -1.42 | — |